Protalix BioTherapeutics Inc (PLX)
1.29
+0.09
(+7.50%)
USD |
NYAM |
May 22, 16:00
1.29
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Research and Development Expense (Annual): 17.09M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.09M |
| December 31, 2022 | 29.35M |
| December 31, 2021 | 29.73M |
| December 31, 2020 | 38.17M |
| December 31, 2019 | 44.62M |
| December 31, 2018 | 33.33M |
| December 31, 2017 | 28.83M |
| December 31, 2016 | 24.61M |
| December 31, 2015 | 20.02M |
| December 31, 2014 | 22.22M |
| Date | Value |
|---|---|
| December 31, 2013 | 26.01M |
| December 31, 2012 | 28.69M |
| December 31, 2011 | 31.04M |
| December 31, 2010 | 29.95M |
| December 31, 2009 | 21.64M |
| December 31, 2008 | 17.40M |
| December 31, 2007 | 13.57M |
| December 31, 2006 | 5.246M |
| December 31, 2005 | 3.773M |
| December 31, 2004 | 1.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.09M
Minimum
2023
44.62M
Maximum
2019
31.79M
Average
29.73M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Agenus Inc | -- |
| InfuSystems Holdings Inc | -- |
| AIM ImmunoTech Inc | 10.94M |
| Perspective Therapeutics Inc | 21.31M |
| Armata Pharmaceuticals Inc | 33.77M |